Literature DB >> 911661

I-fibrinogen as an oncophilic radiodiagnostic agent: distribution kinetics in tumour-bearing mice.

K A Krohn, S J DeNardo, D W Wheeler, G L DeNardo.   

Abstract

Fibrinogen radioiodinated by the iodine monochloride method was tested as a tumour radiodiagnostic agent in mice. The I-fibrinogen cleared from the blood of tumour-bearing mice more rapidly than from that of normal mice, but it cleared from the whole body more slowly, suggesting it accumulated in a substantial tumour-related compartment in the abnormal mice. The tumour concentration steadily increased for 4 h after injection, at which time it reached a peak concentration of 11-4% of the injected dose/g. This concentration was higher than the peak concentration for Ga-citrate (not reached until 24 h) or any other oncophilic radiopharmaceutical tested in this tumour model. The early accumulation is consistent with the use of 123I as a tracer label for fibrinogen. A combination of the large tumour concentration of I-fibrinogen, an increased catabolic rate induced by chemical modification, and the exceptional nuclear properties of 123I for scintigraphic imaging, could lead to a very useful radiodiagnostic procedure for cancer.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 911661      PMCID: PMC2025464          DOI: 10.1038/bjc.1977.182

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  EFFECT OF EPSILON-AMINOCAPROIC ACID ON DEPOSITION OF RADIOIODINATED FIBRINOGEN AND ANTIBODIES TO FIBRINOGEN IN TURPENTINE-INDUCED ABSCESSES ON THE RAT.

Authors:  L E MUTSCHLER
Journal:  Proc Soc Exp Biol Med       Date:  1964-04

2.  Localization of I131 labeled antibody of rat fibrin in transplantable rat lymphosarcoma.

Authors:  I L SPAR; R L GOODLAND; W F BALE
Journal:  Proc Soc Exp Biol Med       Date:  1959-02

3.  Localization in vivo of radio-iodinated anti-rat-fibrin antibodies and radio-iodinated rat fibrinogen in the Murphy rat lymphosarcoma and in other transplantable rat tumors.

Authors:  E D DAY; J A PLANINSEK; D PRESSMAN
Journal:  J Natl Cancer Inst       Date:  1959-02       Impact factor: 13.506

4.  Distribution and elimination of 131 I- and 14C-labelled plasma proteins in the rabbit.

Authors:  S COHEN; R C HOLLOWAY; C MATTHEWS; A S MCFARLANE
Journal:  Biochem J       Date:  1956-01       Impact factor: 3.857

5.  IN VIVO BEHAVIOR OF I-FIBRINOGEN.

Authors:  A S McFarlane
Journal:  J Clin Invest       Date:  1963-03       Impact factor: 14.808

6.  Highly iodinated fibrinogen: a new thrombus-localizing agent.

Authors:  J F Harwig; R E Coleman; S S Harwig; L A Sherman; B A Siegel; M J Welch
Journal:  J Nucl Med       Date:  1975-08       Impact factor: 10.057

7.  Measuring the coagulability of fibrinogen in plasma by isotopic means. Method and principles of its use for in vivo studies.

Authors:  E Regoeczi
Journal:  Thromb Diath Haemorrh       Date:  1967-08-15

8.  An in vivo evaluation of I-fibrinogen labeled by four different methods.

Authors:  R E Coleman; K R Krohn; J M Metzger; M J Welch; R H Secker-Walker; B A Siegel
Journal:  J Lab Clin Med       Date:  1974-06

9.  Human fibrinogen of relatively high solubility. Comparative biophysical, biochemical, and biological studies with fibrinogen of lower solubility.

Authors:  M W Mosesson; N Alkjaersig; B Sweet; S Sherry
Journal:  Biochemistry       Date:  1967-10       Impact factor: 3.162

10.  Comparison of radiolabeled bleomycins and gallium citrate in tumor-bearing mice.

Authors:  K A Krohn; J M Meyers; G L DeNardo; S J DeNardo
Journal:  J Nucl Med       Date:  1977-03       Impact factor: 10.057

View more
  2 in total

1.  The fibrinogen γA/γ' isoform does not promote acute arterial thrombosis in mice.

Authors:  B L Walton; T M Getz; W Bergmeier; F-C Lin; S Uitte de Willige; A S Wolberg
Journal:  J Thromb Haemost       Date:  2014-05       Impact factor: 5.824

2.  Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice.

Authors:  Kellie R Machlus; Jessica C Cardenas; Frank C Church; Alisa S Wolberg
Journal:  Blood       Date:  2011-02-25       Impact factor: 22.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.